Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma.

Liver Cancer · 2025 · PMC12113427 · PMID 40438087

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Anchored MAIC analyses revealed that, in the overall population, HAIC showed a trend toward improved OS compared to atezolizumab-bevacizumab, while no significant difference was observed in PFS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.